Acmopatide
A once-daily signal-biased dual GLP-1/GIP receptor agonist from Carmot Therapeutics, now Roche. Its unusual distinction is that it is one of very few incretin drugs tested in type 1 diabetes, where a 16-week phase 2 produced up to 6.7% weight loss and lower insulin requirements with no diabetic ketoacidosis — but only a small, nominally significant effect on HbA1c.
Acmopatide (CT-868) is an experimental once-daily injection that activates the same two gut-hormone receptors as tirzepatide, from the company Roche bought in 2023. It is unusual for having been tested in type 1 diabetes, where it produced up to 6.7% weight loss and reduced insulin needs over 16 weeks with no cases of ketoacidosis. Its effect on blood sugar in that trial was small. It is not approved anywhere and has never entered phase 3.
What is Acmopatide?
Acmopatide, developed under the code CT-868, is an investigational once-daily subcutaneous peptide that activates both the GLP-1 receptor and the GIP receptor. It came out of Carmot Therapeutics, the South San Francisco company Roche acquired in December 2023 for $2.7 billion, and it is the daily sibling of the better-known weekly asset from the same portfolio, CT-388 (enicepatide). Both are built on the same design idea: rather than maximising receptor activation, they are engineered to be signal-biased, driving cAMP production while recruiting little beta-arrestin, on the theory that avoiding arrestin-mediated receptor internalisation preserves responsiveness during chronic dosing. What makes acmopatide worth a page of its own is not its weight loss, which is modest next to the leading incretins, but where it has been tested. The compound's most substantial trial is in adults with type 1 diabetes and overweight or obesity — a population that incretin drugs have largely avoided, because the headline fear in type 1 diabetes is that reducing insulin requirements and slowing gastric emptying could precipitate diabetic ketoacidosis. In a 16-week phase 2 of 111 participants, no diabetic ketoacidosis and no severe hypoglycaemia occurred, weight fell by 3.3% to 6.7% against a 0.3% gain on placebo, and total daily insulin dose dropped. The glycaemic result was much weaker: HbA1c fell by 0.4 to 0.6 percentage points against 0.3 on placebo, and only the middle dose reached even nominal statistical significance. Acmopatide has not entered phase 3 in any indication. Its development status inside Roche is not something the public record settles, and the company's visible incretin ambitions centre on the weekly CT-388 programme.
What Acmopatide Is Investigated For
Acmopatide has two completed phase 2 trials, both published, and they point in different directions — which is the most useful thing to understand about it. In type 2 diabetes the drug is a strong glucose-lowering agent and a weak weight-loss agent. Over 26 weeks in 103 adults, HbA1c fell by between 1.61 and 2.24 percentage points more than placebo across doses, every comparison at p<0.001, with improvements in fasting glucose, self-monitored glucose profiles and most lipid parameters. Body weight fell only 2.9% more than placebo at the top dose. For a dual GLP-1/GIP agonist in 2026 that weight result is unremarkable; the HbA1c result is not. In type 1 diabetes the pattern inverts. Over 16 weeks in 111 adults with HbA1c between 7.0% and 10.0% and a mean BMI of 34.3, weight fell 3.3% to 6.7% depending on dose against a 0.3% gain on placebo, every comparison at p<0.01, and participants on the two higher doses needed 3.4% to 14.9% less total daily insulin than placebo. Systolic blood pressure fell. But the trial's own primary endpoint was HbA1c, and on that endpoint it produced a 0.4 to 0.6 point reduction against 0.3 on placebo, with a nominally significant placebo-adjusted difference at the 4.1 mg dose only (-0.3 percentage points, 90% CI -0.6 to -0.1, P=0.020) — reported with a 90% confidence interval, which is a phase 2 convention rather than a confirmatory one. The safety observation is the part that matters most for the type 1 setting. Adverse events were primarily gastrointestinal, and there were no episodes of diabetic ketoacidosis and no severe hypoglycaemia. That is the specific hazard that has kept incretins out of type 1 diabetes, and 111 people over 16 weeks is far too small and too short to settle it — but it is a real result rather than an assumption, and it is why this trial was published in a major diabetes journal rather than disappearing.
History & Discovery
Acmopatide began as CT-868 at Carmot Therapeutics, a South San Francisco biotech built around a chemistry platform for discovering peptide and small-molecule drugs against difficult targets. Carmot assembled an incretin portfolio with three visible assets: CT-388, a weekly dual GLP-1/GIP agonist; CT-996, an oral small-molecule GLP-1 agonist; and CT-868, the daily injectable dual agonist that became acmopatide. The programme's clinical work was done under Carmot's own sponsorship. A phase 1 study examined the relationship between insulin secretory response and ambient blood glucose, a second phase 1 study looked specifically at glucose homeostasis in type 1 diabetes, and two phase 2 trials followed — one in type 2 diabetes with overweight or obesity, and one in type 1 diabetes with overweight or obesity. The decision to take an incretin into type 1 diabetes at phase 2 was an unusual one and remains the most distinctive thing about the compound. In December 2023 Roche acquired Carmot for $2.7 billion in cash plus milestone payments, buying the whole portfolio. Roche's subsequent public emphasis has been on the weekly compound, which received the international nonproprietary name enicepatide and entered phase 3 in 2026. Acmopatide received its own nonproprietary name and its two phase 2 trials were published in 2026, in Diabetes, Obesity and Metabolism and in Diabetes Care, but no phase 3 programme has been registered for it. A daily injectable in a field that has standardised on weekly dosing faces an obvious commercial problem regardless of how its data read.
How It Works
Acmopatide copies two gut hormones at once. GLP-1 tells the pancreas to release insulin when blood sugar rises, slows the stomach, and reduces appetite; GIP acts on the pancreas and on fat tissue and appears to improve how the body handles nutrients. Activating both together is the same basic strategy as tirzepatide. What is different is the way acmopatide was tuned: receptors normally get pulled inside the cell and go quiet after repeated stimulation, and this molecule was designed to trigger the useful internal signal while largely avoiding the process that causes that shutdown. It is given as a daily injection rather than a weekly one.
Acmopatide is a synthetic peptide agonist at both the GLP-1 receptor and the GIP receptor, two class B G-protein-coupled receptors expressed on pancreatic beta cells and at numerous sites in the central nervous system, gut and adipose tissue. Agonism at both drives Gs-coupled adenylyl cyclase activity and cAMP accumulation, which in the beta cell potentiates glucose-dependent insulin secretion and in hypothalamic circuits contributes to reduced energy intake. GLP-1 receptor activation additionally slows gastric emptying and suppresses glucagon, while the metabolic contribution of GIP receptor agonism remains an area of genuine scientific disagreement — the same receptor is targeted by agonists and by antagonists in competing clinical programmes. The design feature the developers emphasise is signalling bias. Both acmopatide and its weekly sibling are described as cAMP signal-biased or fully biased, meaning they drive G-protein-dependent cAMP generation with minimal recruitment of beta-arrestin at either receptor. Beta-arrestin recruitment mediates receptor desensitisation and internalisation, so a ligand that largely avoids it should, in principle, maintain receptor responsiveness through chronic daily dosing. This is a mechanistic rationale rather than a demonstrated clinical property: no acmopatide trial was designed to isolate the contribution of bias, and the broader assumption that G-protein-biased agonists escape desensitisation has been directly contradicted in other receptor systems. The pharmacology shows up differently in the two populations studied. In type 2 diabetes, where endogenous beta-cell function persists, the dominant effect was glycaemic: HbA1c reductions of 1.61 to 2.24 percentage points beyond placebo over 26 weeks, with comparatively modest weight loss of 2.9% at the top dose. In type 1 diabetes, where there is essentially no beta cell left to potentiate, the insulin-secretory arm of the mechanism cannot operate, and what remains are the weight, appetite, gastric-emptying and glucagon effects — which is precisely the pattern the trial found, with strong weight and insulin-sparing results and a weak HbA1c result. The two trials together form an unusually clean natural experiment on which parts of incretin pharmacology depend on residual beta-cell function.
Evidence Snapshot
Human Clinical Evidence
Two completed and published phase 2 trials. In type 2 diabetes (NCT05110846, 26 weeks, n=103), HbA1c fell 1.61 to 2.24 percentage points more than placebo, all p<0.001, with 2.9% more weight loss at 4.0 mg and no hypoglycaemia. In type 1 diabetes with overweight or obesity (NCT06062069, 16 weeks, n=111), the primary HbA1c endpoint was weak — 0.4 to 0.6 points versus 0.3 on placebo, nominally significant for 4.1 mg only (P=0.020, 90% CI) — while weight fell 3.3% to 6.7% versus a 0.3% gain, insulin requirements fell, and no diabetic ketoacidosis or severe hypoglycaemia occurred. Two phase 1 studies of 32 participants each preceded them. No phase 3 trial is registered.
Animal / Preclinical
Not the strength of this programme's public record. The incretin receptor pharmacology underlying acmopatide is among the best-characterised in metabolic disease, but compound-specific preclinical data have been presented mainly in conference and corporate materials rather than in the peer-reviewed literature.
Mechanistic Rationale
Strong for dual incretin agonism, which is validated by approved drugs in the same class. Weaker and untested for the signalling-bias hypothesis that distinguishes this compound, which has not been isolated in any clinical comparison.
Research Gaps & Open Questions
What the current literature has not yet settled about Acmopatide:
- 01Whether the absence of diabetic ketoacidosis in the type 1 diabetes trial holds up. 111 participants over 16 weeks cannot detect an event that occurs at a rate of a few per hundred patient-years, and that rate is exactly what the question is about. Only a larger and longer trial answers it.
- 02Whether the weak HbA1c result in type 1 diabetes reflects the drug, the dose, the 16-week duration, or the biology — in a population with essentially no residual beta-cell function, the insulin-secretory arm of incretin pharmacology cannot contribute, so a small glycaemic effect may be the expected result rather than a disappointing one.
- 03Whether signalling bias confers any clinical advantage. No trial of acmopatide was designed to isolate it, there is no non-biased comparator, and the general premise that G-protein-biased agonists avoid receptor desensitisation has been contradicted in other receptor families.
- 04How acmopatide compares with tirzepatide, semaglutide or its own weekly sibling. Every comparison available today is across trials with different populations, durations and endpoints, which is not a comparison at all.
- 05What happens to the programme. Both phase 2 trials are complete and published, no phase 3 is registered, and Roche has not publicly stated whether acmopatide is being developed, parked, or kept as a backup to the weekly compound.
- 06Whether a daily injectable has a viable place in a field that has standardised on weekly dosing — a commercial question rather than a scientific one, but the one most likely to determine whether this compound is ever seen again.
Forms & Administration
Once-daily subcutaneous injection in all reported trials, at doses of 1.75 to 4.0 mg in type 2 diabetes and 1.8, 4.1 or 6.6 mg in type 1 diabetes, compared against volume-matched placebo. Daily dosing distinguishes it from most of the current incretin field, where weekly administration — including its sibling CT-388 — has become the commercial standard, and that difference is one plausible reason the weekly compound became Roche's lead. No approved formulation exists in any country, and the drug is not available through any legitimate channel outside a clinical trial. All injectable peptides should be used only under the supervision of a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no approved dose. In trials, acmopatide was given once daily by subcutaneous injection: 1.75 mg, 3.25 mg or 4.0 mg in the type 2 diabetes study, and 1.8 mg, 4.1 mg or 6.6 mg in the type 1 diabetes study, each against volume-matched placebo.
Frequency
Once daily in every reported study, in contrast to the weekly dosing used by most of the current incretin class.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
The completed trials ran 26 weeks in type 2 diabetes and 16 weeks in type 1 diabetes. There is no information about exposure beyond those durations.
Protocol Notes
The dose-response is worth reading carefully, because it is not a simple ladder. In type 1 diabetes the middle dose of 4.1 mg was the only one to reach nominal significance on the primary HbA1c endpoint, while the highest dose of 6.6 mg produced the largest weight loss and the largest insulin-dose reduction. That pattern — a middle dose best on one endpoint and the top dose best on another, in a trial of roughly 27 people per arm — is exactly the kind of result that phase 3 trials exist to resolve, and it should not be read as identifying an optimal dose. The type 2 diabetes study carries an unusual methodological wrinkle: supply constraints during the COVID-19 period meant some participants randomised to 4.0 mg never received more than 3.25 mg, and they were analysed as a separate dose arm. That is a transparent way to handle the problem, but it leaves three active arms of 18 to 32 people each rather than two planned ones.
Acmopatide is an investigational drug with no approval in any country and no supply outside clinical trials. Nothing on this page is dosing guidance, and material sold under this name through research-chemical or compounding channels is not the clinical compound.
Timeline of Effects
Onset
Not characterised in detail in the published reports. Incretin pharmacology produces glucose-dependent insulin secretion and gastric-emptying effects from the first doses, and gastrointestinal adverse effects typically appear early and during dose escalation. Weight and HbA1c changes accumulate over weeks.
Peak Effect
Both trials measured their primary outcomes at the end of treatment rather than at an identified plateau — week 26 in type 2 diabetes and week 16 in type 1 diabetes — so no peak effect has been established. Weight loss in the type 1 trial was still being measured at the point the trial ended, which means the 16-week figures are an interim view of a process that had not finished rather than a ceiling.
After Discontinuation
Not reported. Across the incretin class, appetite suppression and the metabolic effects that follow from it reverse after treatment stops, and weight regain is the expected pattern; there is no reason to think acmopatide differs, but no acmopatide-specific withdrawal data exist.
Common Questions
How is acmopatide different from tirzepatide?
Both activate the GLP-1 and GIP receptors, but they differ in dosing and in signalling design. Tirzepatide is injected weekly; acmopatide is injected daily. Tirzepatide engages GIP considerably more strongly than GLP-1, while the Carmot compounds were engineered for a more even balance and, more distinctively, for biased signalling — producing cAMP with little beta-arrestin recruitment, which in principle limits the receptor internalisation that follows repeated stimulation. Whether that design yields any clinical advantage is unknown, because acmopatide has never been compared head to head with tirzepatide. On the evidence that exists, tirzepatide produces far more weight loss.
Why would anyone test a GLP-1 drug in type 1 diabetes?
Because the population has a problem that insulin does not solve. A substantial share of adults with type 1 diabetes also carry overweight or obesity, and the standard treatment makes that harder rather than easier: intensifying insulin to improve glucose control promotes weight gain, and weight gain increases insulin requirements. Incretin drugs attack that loop from the other side. The reason they have mostly been kept out of type 1 diabetes is the fear of diabetic ketoacidosis, which can develop when insulin doses fall, when gastric emptying slows unpredictably, or when illness and reduced food intake coincide. Acmopatide's type 1 trial is notable for reporting no ketoacidosis and no severe hypoglycaemia in 111 participants over 16 weeks, alongside meaningful weight loss and reduced insulin doses.
Did acmopatide work in the type 1 diabetes trial?
It depends which endpoint you read, and the honest answer is that it half worked. The trial's primary endpoint was the change in HbA1c at week 16, and the result there was weak — a 0.4 to 0.6 percentage point fall against 0.3 on placebo, with only the 4.1 mg dose reaching nominal significance, reported against a 90% confidence interval. The secondary endpoints were stronger and more consistent: weight down 3.3% to 6.7% against a slight gain on placebo, insulin requirements down, systolic blood pressure down, and 55.6% of participants on 4.1 mg reaching an HbA1c below 7.0% against 33.3% on placebo. A reader who takes only the headline that acmopatide improved glycaemic control in type 1 diabetes is reading past the primary endpoint.
Is acmopatide available or approved anywhere?
No. It is an investigational compound with no approval in any country, no phase 3 programme registered in any indication, and no legitimate supply outside a clinical trial. Anything sold under the name acmopatide or CT-868 through a research-chemical or compounding channel is not the clinical material and has no verified identity, purity or sterility. Both of its phase 2 trials are complete, and Roche has not publicly set out what happens next with it.
What is signal-biased or cAMP-biased agonism, and does it matter?
When a peptide activates a G-protein-coupled receptor, two things usually happen: a G-protein pathway produces cAMP, which is the therapeutic signal, and beta-arrestin is recruited, which pulls the receptor inside the cell and blunts future responses. A biased agonist is engineered to do more of the first and less of the second, the hope being that receptor responsiveness is preserved across months of dosing. It is a genuinely interesting design idea and the Carmot compounds are built around it. It is also worth knowing that the premise has been challenged elsewhere in pharmacology — in the opioid field, a compound selected for G-protein bias still produced substantial receptor desensitisation through a kinase-dependent route. No trial of acmopatide was designed to test whether its bias produces any clinical benefit, so the rationale remains mechanistic rather than demonstrated.
Who Acmopatide Is NOT For
- •Any use outside a clinical trial — there is no approved product, no established dose and no verified supply.
- •Pregnancy and breastfeeding — no reproductive safety data exist for this compound, and the incretin class is generally avoided in pregnancy.
- •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 — a class-level contraindication for approved GLP-1 receptor agonists, and no acmopatide data exist to say whether it applies here.
- •History of pancreatitis — a class-level caution that has not been specifically evaluated for this compound.
- •Gastroparesis or significant gastrointestinal motility disorder — slowed gastric emptying is a class effect and is a particular hazard in type 1 diabetes, where it complicates insulin timing.
- •Type 1 diabetes outside close specialist supervision — the only type 1 data come from a monitored trial in which insulin doses were actively managed; unsupervised insulin reduction alongside an incretin is how ketoacidosis happens.
Drug & Supplement Interactions
No formal drug-interaction studies have been published for acmopatide. The interactions that matter are those of the class and of the populations studied. Insulin is the central one. In the type 1 diabetes trial, participants on the higher doses needed 3.4% to 14.9% less total daily insulin than placebo, which means that continuing an unchanged insulin regimen alongside this drug would be expected to produce hypoglycaemia, while reducing insulin too aggressively is the route to ketoacidosis. Both edges of that are managed by monitoring, which is why the data come from a supervised trial. Sulfonylureas and other insulin secretagogues carry the same hypoglycaemia concern in type 2 diabetes, and dose reduction is standard practice when an incretin is added to them. Slowed gastric emptying is a pharmacokinetic interaction in its own right: it can delay the absorption of oral medicines, which matters most for drugs with narrow therapeutic windows or time-critical absorption, including oral contraceptives, levothyroxine and some anticonvulsants. Approved incretins carry labelling to this effect; acmopatide has no label and no specific data. Anything that independently raises the risk of ketoacidosis — notably SGLT2 inhibitors, which have their own euglycaemic ketoacidosis signal — would warrant particular caution in combination, though no such combination has been studied with this compound.
Safety Profile
Common Side Effects
Cautions
- • Investigational compound — no regulatory approval anywhere and no phase 3 data
- • In type 1 diabetes, insulin dose reduction and incretin therapy together require close supervision; the absence of ketoacidosis in a 16-week trial of 111 people does not establish safety over longer exposure
- • Gastroparesis and other pre-existing gastrointestinal motility disorders are a recognised concern across the incretin class
- • No pregnancy, lactation, paediatric or renal-impairment data
- • Nothing sold outside a clinical trial under this name has verified identity or purity
What We Don't Know
The entire human safety record consists of two phase 2 trials of 103 and 111 participants lasting 26 and 16 weeks, plus two phase 1 studies of 32 participants each. Nothing is known about exposure beyond six months, about cardiovascular outcomes, about pancreatitis or gallbladder events at the low frequencies that only large trials detect, or about the thyroid C-cell signal that carries a boxed warning for several approved incretins. The ketoacidosis question in type 1 diabetes is the one that most needs a larger and longer answer, and the trial that would provide it has not been run.
Legal Status
United States
Not approved by the FDA for any indication and not available by prescription. Acmopatide is an investigational compound that has completed phase 2 and entered no registered phase 3 programme. It is not a controlled substance. There is no legitimate consumer channel, and any product offered under the name acmopatide or CT-868 outside a clinical trial is of unverified origin.
International
Not approved by the EMA, the UK MHRA, Health Canada, the Australian TGA, Japan's PMDA, or any other regulator. Its trials were run under Carmot Therapeutics and, since the December 2023 acquisition, the asset belongs to Roche.
Sports & Competition
Acmopatide is not named on the WADA Prohibited List, but that does not make it permitted. Section S0, Non-Approved Substances, prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and names drugs under clinical development explicitly. An investigational incretin that has completed phase 2 and is approved nowhere falls squarely inside S0, which applies both in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Acmopatide is approved for type 1 diabetes.
Reality
It is not approved for anything, anywhere. It has completed two phase 2 trials and entered no phase 3. No GLP-1 or dual-incretin agonist is approved for type 1 diabetes in any major market; the trial that makes acmopatide interesting is a 111-person, 16-week phase 2, not a registrational programme.
Myth
The type 1 diabetes trial proved incretins are safe in type 1 diabetes.
Reality
It reported no diabetic ketoacidosis and no severe hypoglycaemia in 111 people over 16 weeks under close trial supervision with active insulin management. That is a genuine and encouraging observation, and it is also far too small and too short to establish the safety of the practice. Ketoacidosis is an uncommon event; detecting or excluding a modest increase in its rate requires thousands of patient-years, not 111 people for four months.
Myth
Acmopatide is a weight-loss drug comparable to tirzepatide or retatrutide.
Reality
The weight results are considerably smaller. In type 2 diabetes it produced 2.9% more weight loss than placebo, where the leading dual and triple agonists report figures several times that in comparable populations. Its type 1 diabetes result of 3.3% to 6.7% over 16 weeks is more respectable but comes from a different population and a shorter trial, and it has never been tested in people with obesity but without diabetes.
Myth
Biased agonism means fewer side effects.
Reality
That is a hypothesis attached to the molecule, not a finding from its trials. Adverse events in both phase 2 trials were predominantly gastrointestinal, which is the familiar pattern for the class. No comparison was built into either trial that could show whether bias reduced side effects, and in other receptor systems the equivalent assumption has not survived testing.
Myth
CT-868 and CT-388 are the same drug under different codes.
Reality
They are different compounds from the same company and the same design philosophy. CT-868 is acmopatide, injected daily, with completed phase 2 trials in type 1 and type 2 diabetes. CT-388 is enicepatide, injected weekly, with much larger weight-loss results and an active phase 3 programme. Roche acquired both in the Carmot transaction; only one of them is visibly moving forward.
Published Research
7 studiesA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity
Diabetes Care 2026, the trial this page is largely built on. 111 adults with type 1 diabetes, HbA1c 7.0–10.0% and BMI at least 27, randomised 1:1:1:1 to once-daily subcutaneous acmopatide 1.8, 4.1 or 6.6 mg or volume-matched placebo for 16 weeks. The primary endpoint, HbA1c change at week 16, was weak: −0.4 to −0.6% against −0.3% on placebo, with a nominally significant placebo-adjusted difference only at 4.1 mg (−0.3%, 90% CI −0.6 to −0.1, P=0.020). Secondary endpoints were stronger — weight −3.3% to −6.7% versus +0.3%, all P<0.01; total daily insulin 3.4% to 14.9% lower than placebo at the two higher doses; systolic blood pressure down. Adverse events were primarily gastrointestinal, with no diabetic ketoacidosis and no severe hypoglycaemia.
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial
Diabetes, Obesity and Metabolism 2026. 103 adults with type 2 diabetes, BMI at least 27 and HbA1c 7.0–10.0%, randomised 1:2:1 to once-daily CT-868 1.75 mg, 4.0 mg or placebo for 26 weeks; COVID-related supply constraints meant some participants assigned to 4.0 mg received no more than 3.25 mg and were analysed as a separate arm. HbA1c fell 1.61 to 2.24 percentage points more than placebo, all p<0.001, with improvements in fasting glucose, self-monitored glucose and most lipids. Weight loss was modest — 2.9% beyond placebo at 4.0 mg. No participant experienced hypoglycaemia, and adverse events were mostly mild or moderate.
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
A Study of CT-868 in Type 1 Diabetes Mellitus (NCT06062069)
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus (NCT05110846)
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes (NCT05794581)
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose (NCT04973111)
Acmopatide Compared
Quick Facts
- Class
- Incretin Mimetic
- Tier
- C
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 7PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.